Bausch Boosts Consumer Growth Platform With Ocuvite Eye Performance
In a market expected to reach $2.85bn in worldwide sales in 2024, Bausch Health's Bausch + Lomb business launches Ocuvite Eye Performance, formulated to help strengthen the macula and protect the eye from stressors such as sun light and blue light emitted from digital devices, in the US while considering expanding distribution to other countries.
You may also be interested in...
"We're investing more to drive growth as we allocate capital to support the launches of new products in the segment like Lumify, for DTC advertising that continue to drive sales growth of other US consumer products like our eye vitamins," says CEO Joseph Papa.
The company reported a second quarter of organic sales growth, though revenues declined because of divestitures. Dermatology and Diversified Products segments continued to face challenges, and the company is working to respond to an FDA CRL for potential new dermatology product Duobrii.
Nutraceutical Corp. refutes California lead claim; CRN Conference, Workshop registration open; GMA appoints Freeman to helm; Ocuvite Blue Light for digital protection; and NIH app for herbals.